Floatz logo

qt-219cx

IgA Nephropathy (IgAN)

The Children's Hospital of Zhejiang University School of MedicineCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the IgA Nephropathy (IgAN) cohort.

Asset / SponsorPhaseRating
VALSARTAN
Columbia University
Phase 4BB
PREDNISONE TABLETS
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2B
BARDOXOLONE METHYL ESTER
Biogen
Phase 2B
Aliskiren
Columbia University
Phase 4CCC
Ucar T-Cell
The Children's Hospital of Zhejiang University School of Medicine
Phase 1CCC
RD06-05 CART Cell
The Children's Hospital of Zhejiang University School of Medicine
Early Phase 1C
Enalapril
National Center for Research Resources (NCRR)
N/AD

Same molecule, other indications

qt-219cx is also rated in:

systemic lupus erythematosusDormant
C
Indicative ·
39 / 100
View asset →
idiopathic multidrug-resistant nephrotic syndromeDormant
C
Indicative ·
39 / 100
View asset →
systemic sclerosisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →